Related Experiment Videos
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
Insights
A common MTHFR gene mutation is linked to higher homocysteine levels, a risk factor for vascular diseases like heart disease. This genetic variant may increase the risk of developing these conditions.
Area of Science:
- Genetics
- Biochemistry
- Cardiovascular Science
Background:
- Hyperhomocysteinaemia is a known risk factor for cerebrovascular, peripheral vascular, and coronary heart disease.
- Elevated plasma homocysteine levels can stem from genetic or nutritional issues affecting homocysteine metabolism pathways.
- 5,10-Methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in folate metabolism and homocysteine remethylation.
Discussion:
- A prevalent MTHFR gene mutation, found in ~38% of chromosomes, alters a key amino acid.
- This mutation is associated with reduced MTHFR enzyme activity and increased thermolability.
- In vitro studies confirm the mutation's detrimental effect on MTHFR enzyme function.
Key Insights:
- Individuals with the homozygous MTHFR mutation exhibit significantly elevated plasma homocysteine levels.
- Reduced MTHFR activity due to this mutation may contribute to vascular disease development.
- The identified MTHFR mutation represents a potential genetic risk factor for vascular disease.
Outlook:
- Further research is warranted to elucidate the precise mechanisms linking this MTHFR mutation to vascular pathology.
- Investigating the prevalence of this mutation in diverse populations can refine risk assessments.
- Exploring therapeutic strategies targeting MTHFR function or homocysteine levels may offer preventative measures.
Abstract:
Hyperhomocysteinaemia has been identified as a risk factor for cerebrovascular, peripheral vascular and coronary heart disease. Elevated levels of plasma homocysteine can result from genetic or nutrient-related disturbances in the trans-sulphuration or re-methylation pathways for homocysteine metabolism. 5, 10-Methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulatory form of folate and carbon donor for the re-methylation of homocysteine to methionine. Reduced MTHFR activity with a thermolabile enzyme has been reported in patients with coronary and peripheral artery disease. We have identified a common mutation in MTHFR which alters a highly-conserved amino acid; the substitution occurs at a frequency of approximately 38% of unselected chromosomes. The mutation in the heterozygous or homozygous state correlates with reduced enzyme activity and increased thermolability in lymphocyte extracts; in vitro expression of a mutagenized cDNA containing the mutation confirms its effect on thermolability of MTHFR. Finally, individuals homozygous for the mutation have significantly elevated plasma homocysteine levels. This mutation in MTHFR may represent an important genetic risk factor in vascular disease.